Compare TMC & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TMC | RARE |
|---|---|---|
| Founded | 2011 | 2010 |
| Country | Canada | United States |
| Employees | 48 | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.7B |
| IPO Year | N/A | 2013 |
| Metric | TMC | RARE |
|---|---|---|
| Price | $4.22 | $33.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 20 |
| Target Price | $8.85 | ★ $59.10 |
| AVG Volume (30 Days) | ★ 5.1M | 3.1M |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.31 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $673,000,000.00 |
| Revenue This Year | N/A | $13.12 |
| Revenue Next Year | N/A | $37.80 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 20.13 |
| 52 Week Low | $3.84 | $18.29 |
| 52 Week High | $11.35 | $39.89 |
| Indicator | TMC | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 37.28 | 68.31 |
| Support Level | $3.93 | $31.82 |
| Resistance Level | $4.89 | $34.01 |
| Average True Range (ATR) | 0.25 | 1.72 |
| MACD | -0.03 | 0.36 |
| Stochastic Oscillator | 26.31 | 70.15 |
TMC The Metals Co Inc is a deep seabed minerals developer focused on the collection, processing and refining of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone (CCZ), approximately 1,500 miles (or 2,400 kilometers) south-west of San Diego, California. The company operates as a single operating and reportable segment, namely exploration of seafloor polymetallic nodules, which includes the development of a metallurgical process to treat such seafloor polymetallic nodules.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.